

Andreas Du Bois

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6452198/publications.pdf>

Version: 2024-02-01

37
papers

9,158
citations

201385

27
h-index

315357

38
g-index

39
all docs

39
docs citations

39
times ranked

9678
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. <i>New England Journal of Medicine</i> , 2016, 375, 2154-2164. | 13.9 | 1,860 |
| 2 | A Phase 3 Trial of Bevacizumab in Ovarian Cancer. <i>New England Journal of Medicine</i> , 2011, 365, 2484-2496. | 13.9 | 1,843 |
| 3 | Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials. <i>Cancer</i> , 2009, 115, 1234-1244. | 2.0 | 1,270 |
| 4 | A Randomized Clinical Trial of Cisplatin/Paclitaxel Versus Carboplatin/Paclitaxel as First-Line Treatment of Ovarian Cancer. <i>Journal of the National Cancer Institute</i> , 2003, 95, 1320-1329. | 3.0 | 950 |
| 5 | Definitions for Response and Progression in Ovarian Cancer Clinical Trials Incorporating RECIST 1.1 and CA 125 Agreed by the Gynecological Cancer Intergroup (GCIg). <i>International Journal of Gynecological Cancer</i> , 2011, 21, 419-423. | 1.2 | 500 |
| 6 | A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms. <i>New England Journal of Medicine</i> , 2019, 380, 822-832. | 13.9 | 373 |
| 7 | GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. <i>Nature Genetics</i> , 2013, 45, 362-370. | 9.4 | 326 |
| 8 | Re: New Guidelines to Evaluate the Response to Treatment in Solid Tumors (Ovarian Cancer). <i>Journal of the National Cancer Institute</i> , 2004, 96, 487-488. | 3.0 | 258 |
| 9 | Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 78-89. | 5.1 | 205 |
| 10 | Addition of Epirubicin As a Third Drug to Carboplatin-Paclitaxel in First-Line Treatment of Advanced Ovarian Cancer: A Prospectively Randomized Gynecologic Cancer Intergroup Trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens. <i>Journal of Clinical Oncology</i> , 2006, 24, 1127-1135. | 0.8 | 190 |
| 11 | Randomized Phase III Trial of Topotecan Following Carboplatin and Paclitaxel in First-line Treatment of Advanced Ovarian Cancer: A Gynecologic Cancer Intergroup Trial of the AGO-OVAR and GINECO. <i>Journal of the National Cancer Institute</i> , 2006, 98, 1036-1045. | 3.0 | 189 |
| 12 | Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer. <i>New England Journal of Medicine</i> , 2021, 385, 2123-2131. | 13.9 | 144 |
| 13 | Influence of Residual Tumor on Outcome in Ovarian Cancer Patients With FIGO Stage IV Disease. <i>Annals of Surgical Oncology</i> , 2010, 17, 1642-1648. | 0.7 | 137 |
| 14 | Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1). <i>PLoS ONE</i> , 2017, 12, e0186043. | 1.1 | 105 |
| 15 | Phase III Trial of Carboplatin Plus Paclitaxel With or Without Gemcitabine in First-Line Treatment of Epithelial Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 4162-4169. | 0.8 | 94 |
| 16 | LION: Lymphadenectomy in ovarian neoplasms—A prospective randomized AGO study group led gynecologic cancer intergroup trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, 5500-5500. | 0.8 | 81 |
| 17 | FIGO stage IV epithelial ovarian, fallopian tube and peritoneal cancer revisited. <i>Gynecologic Oncology</i> , 2016, 142, 597-607. | 0.6 | 64 |
| 18 | Prognostic impact of debulking surgery and residual tumor in patients with epithelial ovarian cancer FIGO stage IV. <i>Gynecologic Oncology</i> , 2016, 140, 215-220. | 0.6 | 62 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Double-Blind, Placebo-Controlled, Randomized Phase III Trial Evaluating Pertuzumab Combined With Chemotherapy for Low Tumor Human Epidermal Growth Factor Receptor 3 mRNA-Expressing Platinum-Resistant Ovarian Cancer (PENELOPE). <i>Journal of Clinical Oncology</i> , 2016, 34, 2516-2525. | 0.8 | 60 |
| 20 | ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: A comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas. <i>Gynecologic Oncology</i> , 2013, 131, 8-14. | 0.6 | 55 |
| 21 | Impact of age on outcome in patients with advanced ovarian cancer treated within a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR). <i>Gynecologic Oncology</i> , 2006, 100, 300-307. | 0.6 | 50 |
| 22 | Surgical management of cardiophrenic lymph nodes in patients with advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2016, 141, 271-275. | 0.6 | 47 |
| 23 | Deleterious somatic variants in 473 consecutive individuals with ovarian cancer: results of the observational AGO-TR1 study (NCT02222883). <i>Journal of Medical Genetics</i> , 2019, 56, 574-580. | 1.5 | 34 |
| 24 | Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association Consortium. <i>Clinical Cancer Research</i> , 2015, 21, 5264-5276. | 3.2 | 33 |
| 25 | Early Modeled Longitudinal CA-125 Kinetics and Survival of Ovarian Cancer Patients: A GINECO AGO MRC CTU Study. <i>Clinical Cancer Research</i> , 2019, 25, 5342-5350. | 3.2 | 33 |
| 26 | Prognostic and predictive value of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) score in surgery for recurrent ovarian cancer. <i>Gynecologic Oncology</i> , 2014, 132, 537-541. | 0.6 | 32 |
| 27 | Pattern and impact of metastatic cardiophrenic lymph nodes in advanced epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2019, 152, 76-81. | 0.6 | 32 |
| 28 | Germline polymorphisms in an enhancer of <i>PSIP1</i> are associated with progression-free survival in epithelial ovarian cancer. <i>Oncotarget</i> , 2016, 7, 6353-6368. | 0.8 | 29 |
| 29 | Impact of Abdominal Wall Metastases on Prognosis in Epithelial Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2016, 26, 1594-1600. | 1.2 | 23 |
| 30 | Polygenic risk modeling for prediction of epithelial ovarian cancer risk. <i>European Journal of Human Genetics</i> , 2022, 30, 349-362. | 1.4 | 23 |
| 31 | Treatment of Elderly Ovarian Cancer Patients in the Context of Controlled Clinical Trials: A Joint Analysis of the AGO Germany Experience. <i>Onkologie</i> , 2012, 35, 76-81. | 1.1 | 21 |
| 32 | Ovarian Cancer-Specific <i>BRCA</i> -like Copy-Number Aberration Classifiers Detect Mutations Associated with Homologous Recombination Deficiency in the AGO-TR1 Trial. <i>Clinical Cancer Research</i> , 2021, 27, 6559-6569. | 3.2 | 9 |
| 33 | Identification of a Locus Near <i>ULK1</i> Associated With Progression-Free Survival in Ovarian Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 1669-1680. | 1.1 | 5 |
| 34 | Low probability of disease cure in advanced ovarian carcinomas before the PARP inhibitor era. <i>British Journal of Cancer</i> , 2022, 127, 79-83. | 2.9 | 5 |
| 35 | Cell-Free-DNA-Based Copy Number Index Score in Epithelial Ovarian Cancer—Impact for Diagnosis and Treatment Monitoring. <i>Cancers</i> , 2022, 14, 168. | 1.7 | 5 |
| 36 | Early treatment modifications improve chemotherapy adherence in ovarian cancer patients >70 years. <i>Gynecologic Oncology</i> , 2019, 153, 616-624. | 0.6 | 4 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | Genomic Instability Is Defined by Specific Tumor Microenvironment in Ovarian Cancer: A Subgroup Analysis of AGO OVAR 12 Trial. <i>Cancers</i> , 2022, 14, 1189. | 1.7 | 3 |